Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
May 13, 2024 07:00 ET
|
Entera Bio Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
October 16, 2023 08:00 ET
|
Entera Bio Ltd.
JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented...
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
January 09, 2023 08:30 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
September 23, 2021 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the...
Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update
September 13, 2021 16:05 ET
|
Rani Therapeutics, LLC
- IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors’ appointments - SAN...
Rani Therapeutics Announces Appointment of Eric Groen as General Counsel
September 09, 2021 08:00 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing...
Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
August 13, 2021 16:05 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing...
Rani Therapeutics Announces Pricing of Initial Public Offering
July 30, 2021 08:56 ET
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to...